Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866 · View on ClinicalTrials.gov ↗
Study Summary
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Conditions Studied
Study Locations (20)
California
- First OC Dermatology — Fountain Valley
- Center for Dermatology Cosmetic and Laser Surgery — Fremont
- University of California — Irvine
- University of California - San Diego/Rady Children's Hospital — San Diego
Arkansas
- Johnson Dermatology — Fort Smith
- University of Arkansas for Medical Sciences — Little Rock
- Arkansas Dermatology — Little Rock
Florida
- Feinstein Dermatology and Cosmetic Surgery — Hollywood
- Academic Alliance in Dermatology — Tampa
- Integrated Dermatology of West Palm Beach — West Palm Beach
Massachusetts
- Integrated Dermatology of Massachusetts — Quincy
- University of Massachusetts Medical School — Worcester
Arizona
- Clear Dermatology & Aesthetics Center/Investigative MD — Scottsdale
District of Columbia
- George Washington University — Washington D.C.
Illinois
- Lurie Children's Hospital/Northwestern University — Chicago
Indiana
- Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2050-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03661866
The ClinicalTrials.gov registry entry for NCT03661866 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Target PharmaSolutions, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03661866 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Arkansas, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03661866 about?
NCT03661866 is a clinical study titled "A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC". TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and com...
What is the current status of trial NCT03661866?
This trial is currently active not recruiting. The enrollment target is 15,000 participants. The study started on 2018-12-21. Estimated completion is 2050-12.
What conditions does trial NCT03661866 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Alopecia Areata, Chronic Spontaneous Urticaria. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03661866?
This trial is sponsored by Target PharmaSolutions, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03661866 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.